Résumé
Primary rhabdoid tumor of lung is a rare histological and clinical entity. Lung tumors with rhabdoid features have been included as variants of large-cell carcinoma in the 1999 World Health Organization (WHO) classification of lung tumors. A large-cell carcinoma with a rhabdoid phenotype (LCCRP) is unusual, with only 38 cases reported till date. We report the clinical details of one such case that was treated with pneumonectomy and adjuvant chemotherapy. We also present a review of the literature. To identify relevant articles, we searched PubMed, Ovid, and IngentaConnect databases using the key words 'rhabdoid,' 'lung cancer,' and 'primary rhabdoid tumor of lung.'
Sujets)
Adulte , Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Association thérapeutique , Femelle , Humains , Immunohistochimie , Tumeurs du foie/anatomopathologie , Tumeurs du foie/secondaire , Tumeurs du foie/thérapie , Tumeurs du poumon/métabolisme , Tumeurs du poumon/anatomopathologie , Tumeurs du poumon/thérapie , Métastase lymphatique/anatomopathologie , Pneumonectomie , Tumeur rhabdoïde/métabolisme , Tumeur rhabdoïde/secondaire , Tumeur rhabdoïde/thérapieRésumé
Ectopic or accessory breast tissue is most commonly located in the axilla, though it may be present anywhere along the milk line. Development is hormone dependent, similar to normal breast tissue. These lesions do not warrant any intervention unless they produce discomfort, thus their identification and distinction from other breast pathologies, both benign and malignant, is essential. We report a case with locally advanced breast cancer who presented with an ipsilateral axillary mass following surgery, radiotherapy, and chemotherapy. Subsequent evaluation with excision biopsy showed duct ectasia in axillary breast tissue and the patient was continued on hormone therapy with tamoxifen.
Sujets)
Adulte , Antibiotiques antinéoplasiques/usage thérapeutique , Antinéoplasiques/usage thérapeutique , Antinéoplasiques hormonaux/usage thérapeutique , Aisselle , Biopsie , Tumeurs du sein/traitement médicamenteux , Carcinome canalaire du sein/traitement médicamenteux , Traitement médicamenteux adjuvant , Épirubicine/usage thérapeutique , Femelle , Études de suivi , Humains , Mastectomie radicale modifiée , Stadification tumorale , Parité , Grossesse , Préménopause , Radiothérapie adjuvante , Récidive , Tamoxifène/usage thérapeutique , Taxoïdes/usage thérapeutique , Facteurs temps , Résultat thérapeutiqueRésumé
Epithelial-myoepithelial carcinoma is a rare tumor which makes up about 0.2% of epithelial neoplasms of the salivary glands; parotid gland being the most common primary site of origin. The tumor may also very rarely originate in minor salivary glands of the base of the tongue. Due to rarity of its occurrence, histogenesis and clear cut therapeutic guidelines are not defined. The present report describes the case of a 48 year old male who was diagnosed to have a tubular variant of epithelial-myoepithelial carcinoma of the base of tongue, Stage T3 N0 M0 (Stage group III). The patient was treated with neoadjuvant chemotherapy followed by radical radiotherapy (Rt) and is alive with no evidence of disease 14 months following end of treatment.